BRIGLIM MV2

Description

BRIGLIM MV2 Tablet is a triple-combination oral medication formulated to manage type 2 diabetes mellitus in adults. It is manufactured by Bricent Healthcare Pvt Ltd .

Composition:

• Glimepiride (2 mg): A sulfonylurea that stimulates the pancreas to release more insulin.

• Metformin Hydrochloride (500 mg, sustained release): A biguanide that decreases hepatic glucose production and enhances peripheral insulin sensitivity.

• Voglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the absorption of carbohydrates from the intestine, thereby reducing postprandial blood glucose spikes.

Mechanism of Action:

• Glimepiride increases insulin secretion from pancreatic beta cells.

• Metformin reduces hepatic glucose production and improves insulin sensitivity.

• Voglibose inhibits enzymes responsible for breaking down complex carbohydrates, slowing glucose absorption.

This combination addresses multiple pathophysiological defects in type 2 diabetes, providing a comprehensive glycemic control strategy.

Indications:

• Management of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy or dual therapy do not provide adequate glycemic control .

Contraindications:

• Hypersensitivity to any of the components.

• Moderate to severe kidney impairment.

• Diabetic ketoacidosis.

• Inflammatory bowel disease or colonic ulcerations.

Precautions:

• Use with caution in elderly patients and those with liver impairment.

• Monitor renal function periodically.

• Not recommended during pregnancy or breastfeeding unless prescribed by a healthcare provider.